Abivax CEO suggests no urgency for deal-making ahead of key trial readout
Source: SeekingAlpha
2026-03-24 13:04:05 ET
More on Abivax
- Abivax: Maintaining 'Strong Buy' On Buyout Speculation And Obefazimod Advancement
- Abivax: Don't Just Buy The Rumor, Buy The Fundamentals
- Abivax reports FY results
- Abivax pares gain after denying AstraZeneca speculation
- Seeking Alpha’s Quant Rating on Abivax
Read the full article on Seeking Alpha
For further details see:
Abivax CEO suggests no urgency for deal-making ahead of key trial readout
Abivax SA
NASDAQ: ABVX
ABVX Trading
9.31% G/L:
$110.51 Last:
534,647 Volume:
$102.39 Open:
ABVX Latest News
March 23, 2026 04:05:00 pm
Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
ABVX Stock Data
$9,359,969,582
53,161,297
N/A
64
N/A
Biotechnology & Life Sciences
Healthcare
FR
Paris
